Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.41 |
| ▸ | ABL1 | P00519 | 11/20 | 0.41 |
| ▸ | HCK | P08631 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.33 |
| ▸ | CSK | P41240 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659762 | 1.00 | SRC (0.41) | SRCABL1HCKEGFRLCK | |
| SCHEMBL23630561 | 0.89 | SRC (0.43) | SRCABL1HCKEGFRLCK | |
| SCHEMBL32659770 | 0.89 | SRC (0.43) | SRCABL1HCKEGFRLCK | |
| SCHEMBL23630530 | 0.80 | SRC (0.42) | SRCABL1EGFRTP53 | |
| SCHEMBL23630560 | 0.79 | SRC (0.43) | SRCEGFRLCKTP53 | |
| SCHEMBL32659774 | 0.79 | SRC (0.44) | SRCABL1HCKEGFRLCK | |
| SCHEMBL23630541 | 0.79 | SRC (0.44) | SRCABL1HCKEGFRLCK | |
| SCHEMBL23630529 | 0.78 | LMNA (0.46) | SRCABL1EGFRTP53 | |
| SCHEMBL23630524 | 0.78 | EGFR (0.42) | SRCEGFRLCKTP53 | |
| SCHEMBL23630555 | 0.77 | MEN1 (0.40) | SRCABL1HCKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | claimed |
| US-12522606-B2 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | UNIVERSITY OF WASHINGTON (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| WO-2021142170-A1 | MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | SRC 1546/4885ABL1 2926/4885HCK 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.